Adverse effects of temozolomide and O6BG on body weight
| Group | Mean nadir weight loss, mean ± SE (%) | Maximum weight gain, mean ± SE (%) | ||
|---|---|---|---|---|
| No modulation | ||||
| ILI + 10% DMSO (control; n = 6) | −6.2 ± 3.2 | 2.7 ± 2.0 | ||
| ILI + 350 mg/kg temozolomide (n = 6) | −5.4 ± 1.0 | 1.2 ± 1.9 | ||
| ILI + 750 mg/kg temozolomide (n = 6) | −3.3 ± 1.3 | 3.1 ± 1.3 | ||
| Modulation with 3.5 mg/kg O6BG | ||||
| ILI + 350 mg/kg temozolomide (n = 6) | −1.8 ± 0.8 | 3.5 ± 1.2 | ||
| ILI + 750 mg/kg temozolomide (n = 6) | −5.3 ± 1.9 | 3.9 ± 1.5 | ||
| Modulation with 3.5 mg/kg O6BG × 5 d | ||||
| ILI + 10% DMSO (control; n = 6) | −3.3 ± 1.4 | 3.0 ± 1.5 | ||
| ILI + 350 mg/kg temozolomide (n = 6) | −6.7 ± 2.9 | 7.3 ± 3.5 | ||
| ILI + 750 mg/kg temozolomide (n = 6) | −7.5 ± 1.6 | 4.4 ± 1.6 | ||
| Systemic 35 mg/kg temozolomide (n = 6) | −8.8 ± 2.9 | 1.6 ± 1.8 | ||